Celebrating 60 years of melanoma research to save lives
19 April 2017
Melanoma Institute Australia is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
It was back in 1957 when Sydney Hospital recorded its first data on a melanoma patient. This patient record marked the beginning of what was to become the Melanoma Research Database (MRD), which is now the biggest database of its kind in the world. With more than 41,000 patient records, the MRD continues to play a vital role in underpinning the ground-breaking work of Melanoma Institute Australia (MIA) and around the world.
“Melanoma used to be viewed as a disease with a dismal outlook for patients, but I am pleased to say that today things are much different,” said Professor Richard Scolyer, MIA’s Conjoint Medical Director. “The foresight of our colleagues at Sydney Hospital to start recording patient data back in 1957 set us on a path towards greater understanding of the disease, and we are now leading the world in advancing melanoma treatment and research.”
“Life expectancy for advanced melanoma patients has tripled in the last five years, and we are even seeing some patients who are recovering fully,” comments Professor Georgina Long, MIA’s Conjoint Medical Director. “However we still have a long way to go, with one Australian dying from melanoma every six hours.”
Critical to our story is the work of Professor Gerry Milton (pictured) of the Sydney Melanoma Unit (now Melanoma Institute Australia) who in 1968 was trying to better understand the disease. He recruited Dr Helen Shaw to collect and collate all the records of melanoma patients treated at Sydney Hospital over the previous decade. Always forward thinking, the Unit decided to embrace the “high technology” of the day and convert the entire patient catalogue to punch cards – and so the database was born. The detailed patient records included diagnosis, treatment and disease course over time.
The MRD database is now managed by a team including IT specialists and clinical data managers, dedicated to its refinement, preservation and cultivation. It serves as an invaluable resource to identify and extract specific sub-sets of information for research projects related to causes, diagnosis, prognosis and treatment outcomes in melanoma patients. The knowledge gained from these studies assists in the management of melanoma patients around the world.
“We celebrate this Diamond Anniversary with much gratitude to our professional predecessors for their pioneering work that was way ahead of its time. We also have immense appreciation for those thousands of melanoma patients who over the last 60 years have allowed their clinical records to be included in our research database which have enabled us to improve the lives of melanoma patients that have followed them,” Professor Scolyer said.
“They have quite literally given the gift of life to other melanoma patients, and will be the unsung heroes when we finally achieve our goal of ending melanoma.”
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.